Celularity Inc

GX Acquisition Corp. II (Nasdaq: GXGX) filed an amended annual report (10-K/A) on May 24, 2021, bearing accession number 0001213900-21-028849. The SPAC, sponsored by GX Sponsor II LLC and targeting the healthcare and life sciences sector, completed its initial public offering in 2020. At the time of filing, the company was in the process of completing its announced business combination with Celularity Inc., a clinical-stage biopharmaceutical company focused on placenta-derived cell therapies for cancer and other indications. The amendment was consistent with a broad wave of SPAC restatements filed following updated SEC guidance on warrant accounting treatment. Sign up for full data on SpacDesk to access complete filing histories, deal timelines, and sponsor analytics.